TY - JOUR
T1 - The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis
AU - Hiligsmann, Michael
AU - Reginster, Jean-Yves
AU - Silverman, Stuart
N1 - Funding Information:
No outside funding supported the writing of this letter. Ollendorf reports advisory board and consulting fees from DBV Technologies, EMD Serano, Gerson Lehman Group, and Sarepta Therapeutics, unrelated to the content of this research letter. Naci reports a grant from the Commonwealth Fund, unrelated to the content of this letter. The other authors have nothing to disclose.
PY - 2020/3
Y1 - 2020/3
N2 - No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.
AB - No funding was involved in the writing of this letter. Outside of the submitted work, Hiligsmann has received research grants through institution from Amgen, Radius Health, UCB, and Teva/Theramex. Reginster has received research grants and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. Silverman has received grant support from Amgen, Radius, and Lilly; consulting fees from Amgen and Radius; has served on scientific advisory boards for Lilly and Amgen; and has served on speakers bureaus for Amgen, Lilly, and Radius.
U2 - 10.18553/jmcp.2020.26.3.334
DO - 10.18553/jmcp.2020.26.3.334
M3 - Comment/Letter to the editor
C2 - 32105170
SN - 2376-0540
VL - 26
SP - 334
EP - 335
JO - Journal of managed care & specialty pharmacy
JF - Journal of managed care & specialty pharmacy
IS - 3
ER -